A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling, Zarah Glad; Sørensen, Jens Benn; Gerds, Thomas Alexander; Bech, Cecilia; Andersen, Claus Bøgelund; Santoni-Rugiu, Eric.
Cancer Chemother Pharmacol
; 70(5): 743-54, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22960937
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Wnt/IL-1ß/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
Novel therapies for malignant pleural mesothelioma.
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.